Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
After 6 months, those taking the semaglutide had average blood sugar reductions of 0.6% to 1.1%, with bodyweight reduction of around 5 pounds for the 14-mg dose
Funding This work was supported by research funding from the Dutch Cancer Society (KWF) (grant #11249) Acknowledgments We would like to acknowledge the High Throughput Screening center, specifically Selma Eising, Vicky Amo-Addae, and Jan Molenaar, at the Princess Mxima Center for their help in performing the drug screen
Always consult with your healthcare provider before starting, stopping, or switching any weight-loss medication
Key Takeaway Orforglipron is poised to become the first oral, non-peptide GLP-1 receptor agonist approved for obesity treatment
After 72 weeks, 62.9% of patients receiving semaglutide achieved steatohepatitis resolution without fibrosis worsening, compared to 34.3% with placebo (difference: 28.7 percentage points
Neurology, 99 (17), e1835e1842
US$ 25.10
US$ 23.56
US$ 28.70
US$ 24.15
US$ 29.34
US$ 25.36
US$ 26.58
US$ 20.40
US$ 26.49
US$ 20.70
US$ 26.00
US$ 21.98
